Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Gastroenterol Hepatol Bed Bench ; 15(2): 108-119, 2022.
Article in English | MEDLINE | ID: mdl-35845307

ABSTRACT

Aim: This meta-analysis aimed to evaluate the association of HIF-1α expression with clinicopathological features and overall survival (OS) of patients with digestive system malignancies. Background: Numerous studies have demonstrated that hypoxia-inducible factor-1α (HIF-1α) is abnormally expressed in various solid tumors. However, the clinicopathological features and prognostic value of HIF-1α expression in patients with digestive system malignancies remain controversial. Methods: A literature search in PubMed, Web of Science, and Scopus databases was performed to identify all relevant studies published in English until 15 October 2020. The pooled effect was calculated to evaluate the association between HIF-1α expression and clinicopathological features and overall survival in cancer patients. Pooled odds ratios (ORs) or hazard ratios (HRs) with a 95% confidence interval (CI) were calculated using fixed- or random-effects model based on between-study heterogeneity. Results: A total of 44 eligible studies with 5,964 patients were included. The pooled results indicated a positive association of HIF-1α overexpression with poor overall survival (OS) (HR=1.990, 95% CI: 1.615-2.453, p<0.001) and disease-free survival (DFS) (HR=1.90, 95% CI: 1.084-3.329, p=0.043). Meta-analysis results showed that HIF-1α level expression was significantly associated with positive lymph node metastasis (OR=1.869, 95% CI: 1.488-2.248, p<0.001), distance metastasis (OR=2.604, 95% CI: 1.500-4.519, p<0.001), tumor stage (OR=1.801, 95% CI: 1.437-2.257, p<0.001) and tumor size (OR=1.392. 95% CI: 1.068-1.815, p=0.014). Conclusion: This meta-data suggest that HIF-1α expression might serve as an independent prognostic marker and a promising therapeutic target in patients with digestive system malignancies.

2.
Asian Pac J Cancer Prev ; 23(5): 1725-1731, 2022 May 01.
Article in English | MEDLINE | ID: mdl-35633558

ABSTRACT

BACKGROUND: Despite the tremendous efforts in finding a valuable markers for risk stratifying gastric cancer (GC) patients; still, management of this cancer faces multiple obstacles. Given this, we designed a study to explore the possible relationship between the tripartite motif-containing 44 (TRIM44) gene expression, and the outcome of the GC patients. METHODS: The real-time quantitative PCR method was used to evaluate the mRNA expression level of TRIM44, and ß-catenin in fresh primary tumor and adjacent normal tissues collected from 40 GC patients. The Pearson's correlation test, Kaplan-Meier method, and Cox proportional-hazards regression were performed to examine the association of TRIM44 expression with some clinicopathological data and the patients' overall survival (OS). RESULTS: The expression level of both TRIM44 and ß-catenin was remarkably higher in GC tissues than in normal tissues (Fold change=1.71, p=0.004). In subgroup analysis based on the TRIM44 expression, pateints with high TRIM44 expression level exhibited poorer overall survival (HR = 1.46, 95% CI: 1.07-1.98, p=0.016). More strikingly, a positive correlation was also found between the expression of TRIM44 and ß-catenin in GC, indicating that TRIM44 might exert its oncogenic activities probably through the ß-catenin axis. CONCLUSION: This study highlighted the potent value of TRIM44 as an independent prognostic factor in gastric cancer and shed light on the probable interplay between this tripartite motif-containing protein and ß-catenin. However, further investigations, especially with a larger sample size, are required to study the effect of TRIM44 in GC more precisely.


Subject(s)
Intracellular Signaling Peptides and Proteins , Stomach Neoplasms , Tripartite Motif Proteins , Gene Expression Regulation, Neoplastic , Humans , Intracellular Signaling Peptides and Proteins/genetics , Prognosis , Stomach Neoplasms/genetics , Tripartite Motif Proteins/genetics , beta Catenin/genetics
3.
Cancer Gene Ther ; 29(6): 814-824, 2022 06.
Article in English | MEDLINE | ID: mdl-34341501

ABSTRACT

Programmed cell death protein-1 (PD-1), as an immune checkpoint molecule, attenuates T-cell activity and induces T-cell exhaustion. Although siRNA has a great potential in cancer immunotherapy, its delivery to target cells is the main limitation of using siRNA. This study aimed to prepare a liposomal formulation as a siRNA carrier to silence PD-1 expression in T cells and investigate it's in vivo antitumor efficacy. The liposomal siRNA was prepared and characterized by size, zeta potential, and biodistribution. Following that, the uptake assay and mRNA silencing were evaluated in vitro at mRNA and protein levels. siRNA-PD-1 (siPD-1)-loaded liposome nanoparticles were injected into B16F0 tumor-bearing mice to evaluate tumor growth, tumor-infiltrating lymphocytes, and survival rate. Liposomal siPD-1 efficiently silenced PD-1 mRNA expression in T cells (P < 0.0001), and siPD-1-loaded liposomal nanoparticles enhanced the infiltration of T-helper 1 (Th 1) and cytotoxic T lymphocytes into the tumor tissue (P < 0.0001). Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.


Subject(s)
Melanoma , Programmed Cell Death 1 Receptor , Animals , Cell Line, Tumor , Humans , Immunity , Liposomes , Melanoma/genetics , Melanoma/therapy , Mice , Programmed Cell Death 1 Receptor/genetics , Programmed Cell Death 1 Receptor/metabolism , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Tissue Distribution
4.
Asian Pac J Cancer Prev ; 22(8): 2445-2451, 2021 Aug 01.
Article in English | MEDLINE | ID: mdl-34452557

ABSTRACT

BACKGROUND AND AIM: Tripartite Motif Containing 16 (TRIM16) is a member of the TRIM protein family which is known to play a suppressor role in development of numerous tumor types. However, a positive correlation between TRIM16 expression and gastric cancer (GC) progress has created a controversial situation that need to be fully delineated.  The aim of this study was to assess the expression level of TRIM16 mRNA and its relationship with ß-catenin, CyclinD, and BCL2 expression in Iranian GC patients and to investigate its possible association with patients' overall survival.  Materials and Methods: The expression level of TRIM16 of fresh primary tumor and adjacent normal tissues in 40 GC patients was evaluated by real-time quantitative PCR method. Moreover, patients were subdivided into high or low expression subgroups based on the TRIM16 expression levels. The relationship between TRIM16 expression level, ß-catenin, Cyclin D, BCL2, some clinicopathological data and prognosis of GC patients was also analyzed. RESULTS: qPCR analysis showed a lower level of TRIM16 in GC tissues (fold change=0.351) in comparison to their matched adjacent noncancerous tissues (p <0.001). Contrary to this, the expression levels of ß-catenin, Cyclin D, and BCL2 genes were up-regulated in cancerous samples. This may explain the tumor suppressive function of TRIM16 in GC; as reduction in TRIM16 expression leads to the accumulation of mRNAs from ß-catenin, Cyclin D, and BCL2 genes and eventually cancer progression. We did not observe any significant correlation between TRIM16 expression and patients' overall survival. Univariate Cox regression analysis indicated that anemia, weight loss, bleeding, stomach ache, and smoking are statistically associated with overall survival; while, multivariate analysis did not support any correlation.  Conclusions: In sum, this study suggests a tumor suppressive role for TRIM16 in gastric cancer and proposes it as a potential candidate for GC prognosis.
.


Subject(s)
Biomarkers, Tumor/metabolism , Stomach Neoplasms/pathology , Tripartite Motif Proteins/metabolism , Ubiquitin-Protein Ligases/metabolism , Aged , Biomarkers, Tumor/genetics , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Prognosis , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Survival Rate , Tripartite Motif Proteins/genetics , Ubiquitin-Protein Ligases/genetics
5.
Acta Pharm ; 60(1): 1-11, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20228037

ABSTRACT

The reversed-phase preparative high performance liquid chromatographic purification of the methanol extract of the fruits of Ribes biebersteinii Berl. (Grossulariaceae) afforded five cyanidin glycosides, 3-O-sambubiosyl-5-O-glucosyl cyanidin (1), cyanidin 3-O-sambubioside (2), cyanidin 3-O-glucoside (3), cyanidin 3-O-(2(G)-xylosyl)-rutinoside (4) and cyanidin 3-O-rutinoside (5). They showed considerable free-radical-scavenging properties in the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay with the RC(50) values of 9.29 x 10(-6), 9.33 x 10(-6), 8.31 x 10(-6), 8.96 x 10(-6) and 9.55 x 10(-6) mol L(-1), respectively. The structures of these compounds were elucidated by various chemical hydrolyses and spectroscopic means. The total anthocyanin content was 1.9 g per 100 g dried fruits on cyanidin 3-glucoside basis.


Subject(s)
Anthocyanins/isolation & purification , Free Radical Scavengers/isolation & purification , Fruit , Glucosides/isolation & purification , Plant Extracts/isolation & purification , Ribes , Anthocyanins/chemistry , Anthocyanins/pharmacology , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , Glucosides/chemistry , Glucosides/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL